Integer Holdings Corporation (NYSE: ITGR) saw its stock plummet 5.11% in pre-market trading on Thursday, despite reporting second-quarter results that met or exceeded expectations and raising its full-year 2025 profit outlook. The medical device contract manufacturer's unexpected stock decline suggests investors may be focusing on other factors beyond the headline numbers.

For the second quarter of 2025, Integer reported adjusted earnings per share of $1.55, in line with analysts' estimates. Sales came in at $476 million, surpassing the expected $464.4 million. The company's Cardio & Vascular segment was particularly strong, with sales increasing 24% year-over-year, driven by new product ramps and acquisitions.

Integer also raised its 2025 full-year guidance, now expecting adjusted EPS growth of 18% to 23%, up from its previous outlook. The company projects full-year revenue between $1.85 billion and $1.876 billion. Despite these positive indicators, the stock's pre-market decline implies that investors may be concerned about other aspects of the report, such as the company's debt levels or potential challenges in maintaining its growth trajectory in an uncertain economic environment.